Place your pharma strategy bets: focused or cheap?
This article was originally published in Scrip
For a pharma company, tax inversion has been such a painless way to make money go further that the theme has somewhat obscured the other motives for industry deal-making. However, with the US Treasury's abrupt tightening of the reins on 22 September (scripintelligence.com, 23 September 2014), it may be time to take a step back and consider what those other drivers might be.
You may also be interested in...
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.